Please assess the completion status of the following clinical trial:

Trial Title: Iodine-131 Anti-B1 Antibody Consolidation for Patients With Non-Hodgkin's Lymphoma Following First-line CHOP

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* male or female subjects age 18 to 80 years, inclusive, with any International Prognostic Index score; treated with 6 or more cycles of first-line CHOP chemotherapy and achieved a PR, CRu, or CR~* de novo diffuse large B-cell NHL according to the REAL classification; Ann Arbor stage III, stage IV, or bulky stage II disease (any mass ≥10 cm in diameter)~* less than an average of 25% of the intratrabecular marrow space involved by NHL in bilateral bone marrow biopsy specimens or \<10% involvement with NHL from unilateral bone marrow biopsy; tumor tissue expressing the CD20 antigen~* ≥60% performance status on the Karnofsky Performance Scale and an anticipated survival of at least 3 months~* absolute neutrophil count (ANC) ≥1500 cells/mm3 and platelet count ≥100,000/mm3~* adequate renal function (serum creatinine \<1.5 × upper limit of normal \[ULN\]) and hepatic function (total bilirubin ≤2.0 × ULN and aspartate aminotransferase \<5 × ULN)~Exclusion Criteria:~* prior radiation, prior biological therapy, or prior chemotherapy other than first-line CHOP~* active bilateral obstructive hydronephrosis~* New York Heart Association class III or IV heart disease or other serious illness~* prior malignancy other than lymphoma (except for adequately treated skin cancer, in situ cervical cancer, or other cancer for which they had been disease-free for \>5 years)~* human immunodeficiency virus infection~* HAMA positive~* brain or leptomeningeal metastases at any time since diagnosis~* active infection requiring intravenous anti-infectives~* pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single Arm (Type: EXPERIMENTAL): tositumomab and iodine I-131 tositumomab

Based on this trial design, predict the completion outcome and termination type (if applicable).